(Q41217704)

28 September 2017

1 reference

title

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia (English)

1 reference

28 September 2017

1 reference

Serenoa repens

1 reference

2

R N Brogden

1 reference

28 September 2017

G L Plosker

1

1 reference

28 September 2017

publication date

1 November 1996

1 reference

28 September 2017

1 reference

28 September 2017

volume

9

1 reference

28 September 2017

issue

5

1 reference

28 September 2017

page(s)

379-395

1 reference

Therapeutic controversies: clinical treatment of benign prostatic hyperplasia

28 September 2017

cites work

1 reference

12 December 2020

[Alternative therapy of benign prostatic hypertrophy--Permixon (Capistan)]

1 reference

12 December 2020

Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency

1 reference

12 December 2020

A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia

1 reference

12 December 2020

LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1

1 reference

12 December 2020

Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia

1 reference

12 December 2020

Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition

1 reference

12 December 2020

Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts

1 reference

12 December 2020

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression

1 reference

12 December 2020

Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens

1 reference

12 December 2020

Treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients

1 reference

12 December 2020

Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate

1 reference

12 December 2020

Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers

1 reference

12 December 2020

Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease

1 reference

12 December 2020

Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils

1 reference

12 December 2020

[Our experience with a hexane extract of Serenoa repens in the treatment of benign prostatic hypertrophy]

1 reference

12 December 2020

Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.

1 reference

12 December 2020

[Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo]

1 reference

12 December 2020

Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal

1 reference

12 December 2020

Benign prostatic hyperplasia and normal prostate aging: differences in types I and II 5 alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels

1 reference

12 December 2020

Benign prostatic hyperplasia: diagnosis and treatment. Guideline overview. Agency for Health Care Policy and Research

1 reference

12 December 2020

[Anti-edematous action of a hexane extract of the stone fruit of Serenoa repens Bartr.]

1 reference

12 December 2020

The development of human benign prostatic hyperplasia with age

1 reference

12 December 2020

The Lipidosterolic Extract fromSerenoa repens Interferes with Prolactin Receptor Signal Transduction

1 reference

12 December 2020

Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-beta-sitosterol

1 reference

12 December 2020

Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase

1 reference

12 December 2020

Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines

1 reference

12 December 2020

Cell type specific expression of steroid 5 alpha-reductase 2.

1 reference

12 December 2020

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

12 December 2020

Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

Comparison of the metabolites formed in rat prostate following the in vivo administration of seven natural androgens

1 reference

12 December 2020

Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat

1 reference

12 December 2020

Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate

1 reference

12 December 2020

Alpha 1-blockers vs 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review

1 reference

12 December 2020

Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate

1 reference

12 December 2020

Changes in the Metabolism of Dihydrotestosterone in the Hyperplastic Human Prostate*

1 reference

12 December 2020

Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism

1 reference

12 December 2020

Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases

1 reference

12 December 2020

Kinetic analysis of 5 alpha-reductase isoenzymes in benign prostatic hyperplasia (BPH)

1 reference

12 December 2020

alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells

1 reference

12 December 2020

The value of permixon in benign prostatic hypertrophy

1 reference

12 December 2020

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

1 reference

12 December 2020

Treatment of benign prostatic hyperplasia. The Scandinavian BPH Study Group

1 reference

12 December 2020

Human prostatic steroid 5α-reductase isoforms—A comparative study of selective inhibitors

1 reference

12 December 2020

Benign prostatic hyperplasia: pathophysiology and pharmacological treatment

1 reference

12 December 2020

Benign prostatic hyperplasia. Medical and minimally invasive treatment options

1 reference

12 December 2020

10.2165/00002512-199609050-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

28 September 2017

1020360362

0 references

1 reference